Posted by Michael Wonder on 28 Nov 2022
Kintara Therapeutics granted fast track designation from FDA for REM-001 for cutaneous metastatic breast cancer
28 November 2022 - Kintara Therapeutics today announced that the US FDA has granted fast track designation to Kintara's REM-001 therapy for the treatment of patients with cutaneous metastatic breast cancer.
REM-001 was studied in four Phase 2/3 clinical trials in patients with cutaneous metastatic breast cancer. who had previously received chemotherapy and/or failed radiation therapy.
